NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SOFIE

SOFIE

Private
VirginiaHealthcare & Life Scienceshttps://sofie.com/

Last Round

Private Equity

Jun 4, 2024

Est. Valuation

$540.43M

Total Funding Raised

$53.15M

Company Overview

SOFIE is a healthcare technology company that develops molecular imaging probes and devices to provide radiopharmaceutical products for in vivo research, assisting physicians in identifying tumors responsive to targeted therapies and enhancing personalized healthcare through innovative theranostics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Imaging, Clinical Trials, Pharma Supply Chain, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

radiopharmaceuticalsradiopharmacy networktheranosticsPET imaging agentscontract manufacturingCDMOradiopharmaceutical CDMOnuclear medicinemolecular diagnosticsPET imagingPylarifyprostate cancer imagingclinical trial supplyradioisotopesradiochemistrycyclotron productionFDGNeuraceqpharma supply chaingovernment contracts

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SOFIE Comparables

Compare SOFIE with similar companies based on industry and business-model similarity.

SOFIE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PharmaLogic Holdings Corp.
87%
PharmaLogic Holdings Corp.
84%
SpectronRx
83%

SOFIE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityJun 4, 2024
Series CNov 4, 2020
Convertible DebtJul 12, 2019
GrantOct 5, 2018
Series BApr 12, 2018
VC Round
Jun 13, 2016

Key People

Founding team and executive leadership

Patrick W. Phelps

President, CEO, Board Member

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 2, 2026

    Developing new radiopharmaceutical FAPI-74 for theranostic use.

  • Oct 5, 2018

    $5M grant from National Cancer Institute and others.

SOFIE Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SOFIE Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SOFIE's valuation, stock price, and market status.

Firmographic Details

HeadquartersVirginia
Employee Range384
Year Founded2008
Last FundingJun 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.